UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Bone marrow transplantation (Basingstoke), 2012-03, Vol.47 (3), p.380-386

2012

Volltextzugriff (PDF)

Mutated and non‐mutated TP53 as targets in the treatment of leukaemia

British journal of haematology, 2008-05, Vol.141 (4), p.445-453

2008

Volltextzugriff (PDF)

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Journal of clinical oncology, 2012-09, Vol.30 (25), p.3093-3099

2012

Volltextzugriff (PDF)

Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion

British journal of haematology, 2004-11, Vol.127 (3), p.285-291

2004

Volltextzugriff (PDF)

PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

British journal of haematology, 2006-01, Vol.132 (2), p.230-236

2006

Volltextzugriff (PDF)

Cytogenetics in chronic lymphocytic leukemia: Chronic lymphocytic leukemia

Seminars in oncology, 1998-02, Vol.25 (1), p.19-26

1998

Volltextzugriff (PDF)

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma

British journal of cancer, 2008-03, Vol.98 (5), p.1001-1005

2008

Volltextzugriff (PDF)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

Proceedings of the National Academy of Sciences - PNAS, 2007-07, Vol.104 (27), p.11406-11411

2007

Volltextzugriff (PDF)

Identification and characterization of two novel human mitochondrial elongation factor genes, hEFG2 and hEFG1, phylogenetically conserved through evolution

Human genetics, 2001-11, Vol.109 (5), p.542-550

2001

Volltextzugriff (PDF)

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Blood, 2014-04, Vol.123 (14), p.2157-2160

2014

Volltextzugriff (PDF)

The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia

Leukemia, 2006-01, Vol.20 (1), p.77-81

2006

Volltextzugriff (PDF)

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope

Blood, 2003-06, Vol.101 (12), p.4952-4957

2003

Volltextzugriff (PDF)

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia

Blood, 2004-11, Vol.104 (9), p.2879-2885

2004

Volltextzugriff (PDF)

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia

Leukemia, 2008-02, Vol.22 (2), p.339-343

2008

Volltextzugriff (PDF)

X‐linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: Comparisons with primary myelofibrosis

American journal of hematology, 2015-03, Vol.90 (3), p.E44-E48

2015

Volltextzugriff (PDF)

Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia

Leukemia, 2005-05, Vol.19 (5), p.871-873

2005

Volltextzugriff (PDF)

Chronic lymphocytic leukemias utilizing the V(H)3-21 gene display highly restricted V(lambda)2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope

Blood, 2003-06, Vol.101 (12), p.4952

2003

Volltextzugriff (PDF)

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

Medical oncology (Northwood, London, England), 2002-01, Vol.19 (2), p.79-86

2002

Volltextzugriff (PDF)

Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation

International journal of cancer, 2008-09, Vol.123 (5), p.1025-1033

2008

Volltextzugriff (PDF)

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life

Cancer, 2006-06, Vol.106 (11), p.2397-2405

2006

Volltextzugriff (PDF)

Strikingly homologous immunoglobulin gene rearrangements and poor outcome inV(H)3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

Blood, 2006-04, Vol.107 (7), p.2889

2006

Volltextzugriff (PDF)

O-17 Thalidomide analogue CC5013 (revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5Q deletion

Leukemia research, 2005, Vol.29, p.S6-S6

2005

Volltextzugriff (PDF)

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens

British journal of haematology, 2006-11, Vol.135 (3), p.367-373

2006

Volltextzugriff (PDF)

Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way

Läkartidningen, 2009, Vol.106 (49), p.3342

2009

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(89)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(75)
Humans
(51)
Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Biological And Medical Sciences
(29)
Hematology
(29)
Medical Sciences
(28)
Middle Aged
(27)
Hematologic And Hematopoietic Diseases
(25)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(25)
Aged
(23)
Female
(22)
Male
(22)
Adult
(19)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(19)
Oncology
(17)
Medicin
(11)
Medicine
(11)
Prognosis
(11)
Klinisk Medicin
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries

Mutated and non‐mutated TP53 as targets in the treatment of leukaemia

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion

PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

Cytogenetics in chronic lymphocytic leukemia: Chronic lymphocytic leukemia

Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

Identification and characterization of two novel human mitochondrial elongation factor genes, hEFG2 and hEFG1, phylogenetically conserved through evolution

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

X‐linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: Comparisons with primary myelofibrosis

Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia

Chronic lymphocytic leukemias utilizing the V(H)3-21 gene display highly restricted V(lambda)2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life

Strikingly homologous immunoglobulin gene rearrangements and poor outcome inV(H)3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

O-17 Thalidomide analogue CC5013 (revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5Q deletion

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens

Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way

Suchergebnisse filtern